Phase 1 trial of ADI-PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors.

Shuyang YaoFilip JankuKimberly KoenigApostolia-Maria TsimberidouSarina Anne Piha-PaulNai ShiJohn StewartAmanda JohnstonJohn BomalaskiFunda Meric-BernstamSiqing Fu

Published in: Cancer medicine (2021)

Concurrent IM injection of ADI-PEG 20 at 36 mg/m2 weekly and intravenous infusion of PLD at 20 mg/m2 biweekly had an acceptable safety profile in patients with advanced ASS1-deficient solid tumors. Further evaluation of this combination is under discussion.

Keyphrases

drug delivery
cancer therapy
low dose
high dose
squamous cell carcinoma